Tim Smith

These data highlight differences and similarities among dermatologists globally in their decisions related to the treatment of mild-to-moderate atopic dermatitis.

Baricitinib treatment was safe among patients with alopecia areata over 48 weeks in a real-world treatment setting.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode highlights 5 key dermatology updates from the 2025 American Academy of Dermatology Annual Meeting in Orlando.

Investigators highlight systemic treatments for psoriatic disease that maintain lower rates of serious infections among older adults suffering from psoriatic disease.

These recent data demonstrate small doses of doxycycline, an anti-inflammatory medication, may help manage lymphocytic scarring alopecia.

This March 2025 SOCS News Update highlights misconceptions related to skin health, the value of diversity in clinical research, and SOCS Symposium highlights.

These data highlight the potential benefit of continuous treatment with subcutaneous spesolimab for generalized pustular psoriasis (GPP).

These pivotal phase 3 data on povorcitinib were the results of the STOP-HS clinical trial, with results suggesting both efficacy and safety for hidradenitis suppurativa.

New data presented at AAD 2025 point to impacts on multiple disease nodes as needed to achieve high levels of efficacy.

These data, presented at AAD 2025, highlight the efficacy of upadacitinib in clearing skin among patients with atopic dermatitis compared to those given dupilumab.

These data presented at AAD 2025 indicate sustained 2-year disease control in key hidradenitis suppurativa (HS) symptoms with bimekizumab-bkzx treatment.

A panel discussion at the Skin of Color Society Scientific Symposium features 3 notable speakers highlighting dermatology residency questions and more.

In these survey findings, a variety of notable findings regarding perceptions of awareness of CHE as well as views on available drugs are highlighted.

This quiz, the third in a series of 4, tests one's knowledge on prevention and treatment of actinic keratosis based on the 2021 AAD guidelines.

This summary, featuring 4 leading experts, provides an overview of what dermatologists may look forward to during the AAD 2025 Annual Meeting.

This Month in Review summary highlights various news highlights featured in February’s dermatology news coverage.

In this episode, Victoria Barbosa, MD, MPH, MBA, and Janiene Luke, MD, highlight insights and misconceptions about alopecia.

These phase 3 data on delgocitinib cream (Anzupgo) 20 mg/g highlight the drug’s potential for adolescents aged 12 years and older with chronic hand eczema (CHE).

Kernizan discusses winning the 2024 Society for Pediatric Dermatology Medical Student Mentorship Award and getting into pediatric dermatology as a student.

In this analysis, investigators demonstrated that risankizumab led to improvements in palmoplantar pustulosis (PPP) that continued through to Week 68.

These data point to the necessity of quality and usability when using smartphone photographs of skin conditions in emergency departments.

In this interview, Druskovich highlights her experiences being mentored through the Society for Pediatric Dermatology’s Medical Student Mentorship Award.

These data highlight the unique burdens faced by patients with generalized pustular psoriasis (GPP) compared to those of patients with psoriasis vulgaris.

These data provide a potential option for those suffering from hidradenitis suppurativa, as off-label treatment with botulinum toxin type X led to positive findings in patients.

These data point to increasing omega-3 consumption as a potential preventive strategy against atopic dermatitis.

In this analysis, investigators sought evaluate the effectiveness and safety of adding low-dose oral minoxidil to the standard anti-inflammatory treatment of lichen planopilaris.

These data suggest that psoriasis treatment algorithms may benefit younger patients if they implement a step-down rather than step-up approach to biologic use.

These findings highlight the prevalence of atopic dermatitis among adults in France, as well as the different factors associated with various disease profiles.

These phase 3 findings from the INTEGUMENT-PED clinical trial highlight the efficacy and safety of roflumilast cream 0.05% for pediatric patients with atopic dermatitis.

Investigators in China developed a patch test designed for hair care products tailored to clinical needs such as those of patients with conditions like alopecia areata.